CD4 News and Research

RSS

SpyCatcher-SpyTag technology used to develop recombinant protein-based intranasal vaccine against SARS-CoV-2

The findings of a new study showed that the intranasal SpyCage vaccine platform can be protective against SARS-CoV-2 and may prove to be a versatile and adaptable modality for the formulation of intranasal vaccines that target respiratory pathogens.

31 Oct 2022

An innovative nasal vaccine strategy to combat COVID

In a recent study published in the journal Science, researchers at Yale University developed a novel coronavirus disease 2019 (COVID-19) vaccination strategy termed 'prime and spike' (P&S) that leveraged existing systemic immunity triggered by parenteral vaccination (prime) to boost immunity at the respiratory mucosa.

31 Oct 2022

New report on the impact of monkeypox on people with HIV

Researchers describe the presentation of patients severely infected with the monkeypox virus.

30 Oct 2022

Updapted BA.4/5 COVID vaccines boost protection but might not surpass original formula

In a recent study posted to the bioRxiv* preprint server, researchers at Beth Israel Deaconess Medical Center assessed the immunogenicity associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) BA.5 bivalent messenger ribonucleic acid (mRNA) vaccine boosters.

27 Oct 2022

What is the association between regular physical activity and vaccination against COVID-19 among healthcare workers?

Researchers assessed the association between daily physical activity and COVID-19 vaccination among HCWs.

27 Oct 2022

First-time sexual intercourse associated with increases in vaginal immune activity in young women

The changes detected may have important implications for sexually transmitted infection (STI) risk. But the authors do not yet know if the changes increase or decrease the risk of acquiring an STI.

26 Oct 2022

COVID-19 and the gut

Researchers summarize current knowledge about underlying mechanisms and potential therapeutic approaches for the effects of COVID-19 on the gut.

26 Oct 2022

Researchers design a COVID-19 vaccine construct using hybrid SARS-CoV-2 spike protein and nucleocapsid protein peptides

Researchers designed a COVID-19 vaccine construct using hybrid SARS-CoV-2 S protein (containing SARS-CoV-2 Delta and Omicron variant mutations) and N protein peptides that confer T lymphocyte-mediated immune protection.

25 Oct 2022

Immune response in SARS-CoV-1 survivors after COVID-19 vaccination

Researchers evaluate SARS-CoV-2 vaccine-induced immune responses in SARS survivors.

23 Oct 2022

Adaptive immune responses in adults of various ages receiving 2 doses of the BNT162b2 mRNA vaccine

Researchers assessed the correlation between immunosenescence and poor COVID-19 vaccination outcomes in older adults.

21 Oct 2022

Three-dose regimen of HEPLISAV-B vaccine fully protects people living with HIV, data shows

The AIDS Clinical Trials Group (ACTG), the world's largest HIV research network whose focus has expanded to include evaluating outpatient treatment for COVID-19, today presented a session demonstrating that a three-dose regimen of the HEPLISAV-B vaccine fully protected people living with HIV at IDWeek 2022, taking place in Washington D.C. from October 19-22, 2022.

20 Oct 2022

Exploring molecular docking and molecular dynamics simulations as advanced tools for novel antiviral drug discovery

Researchers presented an overview of factors influencing emerging infectious diseases. They also highlighted the importance of molecular dynamic (MD) simulations and molecular docking (MDO) analysis for combating these diseases.

17 Oct 2022

Could COVID-19 infections trigger a relapse of mycosis fungoides or other cutaneous T-cell lymphomas?

Recently, authors highlighted the potential role of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections in triggering the relapse of mycosis fungoides, a type of cutaneous T-cell lymphoma.

17 Oct 2022

HIV patients with moderate immune suppression at greater risk of severe COVID-19 "breakthrough" infection

People with HIV who have moderate immune suppression appear to be at greater risk of severe COVID-19 "breakthrough" infection after vaccination, according to a study led by researchers at the Johns Hopkins Bloomberg School of Public Health.

13 Oct 2022

What is the association between interferon genes and complement regulatory protein expressions in SARS-CoV-2 infections?

Researchers investigated the expression of complement regulatory proteins (CRPs) in coronavirus disease 2019 (COVID-19) to identify potential dysregulated CRP patterns and investigate whether they contribute to COVID-19 pathogenesis.

13 Oct 2022

Antibody response trajectories among solid organ transplant recipients in association with mycophenolate mofetil administration

Researchers explored the trajectory of antibody (Ab) titers after coronavirus disease 2019 (COVID-19) vaccination among solid organ transplant recipients (SOTs) with or without mycophenolate mofetil (MMF), or withdrawn from MMF.

11 Oct 2022

Metformin reduces risk of severe COVID-19 in diabetic patients

A new study determines whether antidiabetic agents can reduce complications in COVID-19 patients with diabetes.

10 Oct 2022

Exploring the biomarker profiles in severe COVID-19

In new research, researchers estimated the D-dimer levels and characterized lymphocyte subsets and cytokine profiles in severe coronavirus disease 2019 (COVID-19) patients.

7 Oct 2022

Study suggests an immunological benefit of combining previous natural infection with vaccination against COVID-19 using a combination of different vaccine platforms

Researchers explored SARS-CoV-2-targeted immune responses among COVAC1 participants who received a novel saRNA vaccine followed by the mRNA BNT162b2 vaccine BNT162b2 vaccine, with or without prior COVID-19 history.